● Recruiting

Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation

Condition: Non-proliferative Diabetic Retinopathy (NPDR) · Open-angle Glaucoma (OAG) · Normal Tension Glaucoma (NTG) · Sponsor: Qlaris Bio, Inc.

PhasePhase 2

Planned participants14

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

Pilot, single-site, prospective study of QLS-111 0.015 % in subjects with NPDR, OAG or NTG

This description comes directly from the study's public registry record.

Talk to the study team

Lisa Brandano · 978-930-2103 · lbrandano@qlaris.bio

Always discuss trial participation with your own doctor first.

Locations (1)

Stanford University, Dept. of Ophthalmology

Palo Alto, California, United States

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07354477